Going from Wegovy 0.25mg to 0.5mg: what to expect at the first dose increase

Why does Wegovy start at 0.25mg rather than a higher dose?

Semaglutide slows gastric emptying and suppresses appetite through the GLP-1 pathway, which also means the gut needs time to adapt. Diving straight into a therapeutic dose would almost certainly mean a rough few weeks, nausea, vomiting, and the kind of indigestion that puts people off continuing. If you want to understand exactly what to expect from this first step, our guide to the Wegovy 0.25mg dose covers what the pen is designed to do and why it works the way it does. Clinical trial data published in the STEP 1 study in the New England Journal of Medicine involved a structured escalation precisely because tolerability during titration directly affects whether people stay in treatment long enough to see meaningful results.

This means the 0.25mg phase is not a disappointment, it is by design. Most people notice little appetite change in the first four weeks, and that is completely expected. The dose is doing groundwork your gut will thank you for later. If you are curious about what the full schedule looks like beyond this first step, the Wegovy dose schedule sets it out clearly.

One practical check worth doing in the first week: look at the pen after each injection and confirm the dose window shows the correct strength. It takes under a minute and rules out any mix-up if you are storing more than one pen at home.

What actually changes when you move to 0.5mg?

The 0.5mg pen delivers twice the semaglutide of the starter dose in each weekly injection. Most people notice a more definite reduction in hunger from this point, meals feel filling sooner, snacking urges quiet down, and the sense of food being less central to the day that Wegovy is known for often becomes clearer. That said, individual responses vary considerably. Some people feel a marked difference within days of the first 0.5mg injection; others notice a more gradual shift over the four weeks on this dose.

Side effects tend to resurface or sharpen at any dose increase, including this one. Nausea is the most commonly reported, typically mild to moderate and transient, settling for most people within one to two weeks. Loose stools, indigestion, and burping are also common. The NHS semaglutide medicines page lists the full side-effect profile and the signs that warrant a call to your prescriber. Staying well hydrated and eating smaller, lower-fat meals during the adjustment period helps most people get through the first week or so without needing to pause.

It is worth understanding what the 0.5mg dose is not: it is still a stepping-stone. Weight loss at this level tends to be modest compared with what accumulates at higher doses. The real clinical gains build over the full titration toward 2.4mg, and now, with the MHRA's approval of the 7.2mg pen, potentially beyond that for some patients. For a fuller picture of how the pens and strengths relate to each other, this page on the 0.25mg pen format explains the volume-versus-strength distinction that often confuses people.

How does the prescriber decide you are ready to increase?

The standard guidance is four weeks at 0.25mg before moving to 0.5mg, but that four-week mark is a minimum, not an automatic green light. Your prescriber will want to know how tolerability has been. Significant nausea, persistent vomiting, or any concerning symptoms are reasons to stay at the current dose for a further four weeks before attempting the increase. Rushing the titration to get to a higher dose faster tends to backfire, people who push through poor tolerability are more likely to stop treatment altogether.

At a regulated service like nume, a real clinician reviews your case before each repeat or dose change, your progress and how you have been feeling genuinely shapes the decision. That is different from an automated system that issues repeat prescriptions without clinical input. Our clinical team's approach is built around exactly this kind of individual assessment at every stage, not a one-size schedule applied mechanically.

If you want to understand the difference between the 0.25mg and 0.5mg doses in more clinical detail before your next review, the comparison of Wegovy 0.25mg and 0.5mg covers the evidence behind each. And if cost at this stage of treatment is on your mind, the Wegovy cost page breaks down what private treatment typically includes beyond the pen itself.

What if side effects at 0.5mg are harder to manage than at 0.25mg?

This happens, and it does not mean treatment has failed. The key distinction is between side effects that are uncomfortable and those that are clinically significant. Mild-to-moderate nausea that eases after a week or two is expected. Severe or persistent vomiting, signs of dehydration, or any sudden severe abdominal pain that radiates to the back (symptoms that could indicate pancreatitis) require prompt medical attention rather than waiting it out. The MHRA flagged pancreatitis as a known but infrequent risk for GLP-1 medicines in a Drug Safety Update in early 2026; any suspected side effects can also be reported directly via the Yellow Card scheme.

If side effects at 0.5mg are genuinely disruptive, the right step is to contact your prescriber rather than stopping the pen unilaterally. Staying at 0.5mg for a longer period, adjusting meal composition, or timing the injection differently are all options a prescriber can discuss with you. The Wegovy 0.5mg page goes into more detail on managing this dose specifically. Stopping suddenly without clinical guidance is rarely the best answer, and if you have questions between doses, our support team is available seven days a week.